Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections

Exclusion Criteria

• •1. Existence of complications of influenza or ARVI (including the presence / development of bacterial infection).
• •2. Hypersensitivity to excipients of the drug XC221 or placebo.
• •3. Antiviral medications in 7 days prior to screening (antiviral agents, interferons and interferon inducers, drugs that have immunomodulating action) or anti-infective agents of systemic or local action.
• •4. Severe infection with signs of cardiovascular insufficiency development and other manifestations of infectious-toxic shock, as well as with the presence of neuroinfection syndrome (encephalic and meningoencephalic reactions, polyradiculoneuritis, neuritis).
• •5. Signs of the development of viral pneumonia (the presence of two or more of the following symptoms): dyspnea, chest pain when coughing, systemic cyanosis, dullness of percussion sound with a symmetrical evaluation of the upper and lower sections of the lungs).
• •6. Infectious diseases during the last week before including into the study.
• •7. History of bronchial asthma.
• •8. History of increased convulsive activity.
• •9. Severe, decompensated or unstable somatic diseases (any diseases or conditions that are life-threatening or may worsen the patient's prognosis, and make him/her ineligible for the clinical study).
• •10. History of oncological diseases, HIV, tuberculosis.
• •11. Diabetes mellitus.
• •12. Drug or alcohol abuse.
• •13. Participation in any other clinical trial in the last 90 days.
• •14. Pregnancy or lactation.
• •15. Military or prison populations.
• •16. Impossibility or inability to comply with the study procedures.
• •17. A member of the investigator's family or other person interested in the results of the study.
• •18. Abnormal laboratory results, which, according to the study doctor, interfere with the patient's inclusion in the study.
• •19. History of renal insufficiency.